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The essential splicing factor SF2/ASF and the heterogeneous nuclear ribonucleoprotein Al (hnRNP Al)
modulate alternative splicing in vitro of pre-mRNAs that contain 5' splice sites of comparable strengths
competing for a common 3' splice site. Using natural and model pre-mRNAs, we have examined whether the
ratio of SF2/ASF to hnRNP Al also regulates other modes of alternative splicing in vitro. We found that an
excess of SF2/ASF effectively prevents inappropriate exon skipping and also influences the selection of mutually
exclusive tissue-specific exons in natural 1-tropomyosin pre-mRNA. In contrast, an excess of hnRNP Al does
not cause inappropriate exon skipping in natural constitutively or alternatively spliced pre-mRNAs. Although
hnRNP Al can promote alternative exon skipping, this effect is not universal and is dependent, e.g., on the size
of the internal alternative exon and on the strength of the polypyrimidine tract in the preceding intron. With
appropriate alternative exons, an excess of SF2/ASF promotes exon inclusion, whereas an excess of hnRNP Al
causes exon skipping. We propose that in some cases the ratio of SF2/ASF to hnRNP Al may play a role in
regulating alternative splicing by exon inclusion or skipping through the antagonistic effects of these proteins
on alternative splice site selection.
Pre-mRNA splicing is an essential process in the expres-
sion of most eukaryotic protein-coding genes. The 5' and 3'
splice sites and the branch site, which exhibit limited se-
quence conservation, are necessary but not sufficient for the
accuracy of splicing (for reviews, see references 21, 35, and
55). In the case of constitutively spliced pre-mRNAs, strict
fidelity in splice site selection is necessary for correct protein
synthesis. On the other hand, flexibility in the recognition of
alternative splice sites can result in an increase in the coding
capacity of many genes and allows the possibility of regu-
lating the process of splicing. Thus, many genes can express
multiple protein isoforms by alternative splicing, often in a
tissue-specific or developmentally regulated manner (for
reviews, see references 41 and 59). To investigate the
molecular mechanisms responsible for the specificity of
constitutive and alternative splice site selection, we are
characterizing several protein factors that can modulate the
selection of alternative splice sites in vitro.
A versatile mode of regulated alternative splicing involves
a choice between exon inclusion and exon skipping (for a
review, see reference 59). To date, several cis-acting ele-
ments and trans-acting factors have been reported to influ-
ence alternative exon selection in a number of systems. The
importance of internal exon length, and of a downstream
intron element, for neuron-specific Ni exon inclusion during
alternative splicing of src pre-mRNA has been documented
(5, 6). A deletion within exon 19 of the dystrophin gene,
leading to skipping of this exon, is the basis for one form of
Duchenne muscular dystrophy (43). In vitro splicing of
preprotachykinin pre-mRNA suggested that the strength of
the downstream 5' splice site and its interaction with Ul
small nuclear ribonucleoprotein determines whether an al-
ternative exon is included (20, 38). In some pre-mRNAs,
* Corresponding author.
specific elements in the alternative exon influence its inclu-
sion (10, 23, 24, 40, 42, 62). Another critical factor for the
selection of internal alternative exons is the relative strength
of the competing splice sites, as influenced, for example, by
the composition of the polypyrimidine tract upstream of the
3' splice site in the preceding intron (12, 23, 29, 40, 50). A
recent exon definition model proposes that internal exons
are defined by recognition of the upstream 3' splice site,
followed by a search for the downstream 5' splice site (56,
61). Recently, systematic in vitro and in vivo analyses of
model pre-mRNAs showed that several cis-acting elements,
including the 5' and 3' splice sites, the branch site, the
polypyrimidine tract, the length of the internal exon, and the
downstream intron, cooperate to determine the selection of
the internal exon (12, 13).
We have reported that the essential human splicing factor
SF2/ASF (17, 37), which is a member of the SR protein
family (63), and heterogeneous nuclear ribonucleoprotein Al
(hnRNP Al) regulate alternative pre-mRNA splicing in vitro
through antagonistic effects on 5' splice site selection. Prox-
imal 5' splice sites are preferred at high concentrations of
SF2/ASF, whereas distal 5' splice sites are favored at high
concentrations of hnRNP Al (16, 33, 44). SF2/ASF was also
shown to cause retention of an alternative adenovirus ElA
intron by a mechanism other than 5' splice site competition
(26). Recently, the splicing factor SC35, which is also a
member of the SR protein family (14, 63), was shown to have
in vitro splicing activities equivalent to those of SF2/ASF
(15). Furthermore, it was shown that both SF2/ASF and
SC35 also favor the proximal site in a pre-mRNA containing
duplicated 3' splice sites. This effect is counteracted not by
hnRNP Al but rather by an activity designated SF7 (15, 45),
which is potentially related to an activity that regulates
utilization of an adenovirus 3' splice site in vitro (64). Thus,
in constitutively spliced pre-mRNAs, the combined stimula-
tion of proximal 5' and 3' splice sites by SF2/ASF or SC35
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may be part of the cellular mechanisms that prevent inap-
propriate exon skipping and ensure the accuracy of splicing,
whereas an excess of hnRNP Al (or SF7) might be expected
to cause inappropriate exon skipping, which should be
deleterious to the cell. On the other hand, the mechanisms of
alternative exon inclusion and skipping may be governed at
the level of 5' and/or 3' splice site selection and could also
involve SF2/ASF and hnRNP Al. To address these ques-
tions, we have examined the influence of SF2/ASF and
hnRNP Al on splice site selection in vitro, using several
natural and model constitutively or alternatively spliced
pre-mRNAs.
MATERIALS AND METHODS
Preparation of human SF2/ASF and recombinant hnRNP
Al. The preparation of sonicated nuclear extract from 24
liters of HeLa cells (approximately 2.4 x 1010 cells) was
described previously (32). SF2/ASF was recovered in the
60%- to 90%-saturated (NH4)2SO4 pellet (57), leading to
greater enrichment than in the 50 to 80% cut described
originally (32). The pellet containing SF2/ASF was resus-
pended in 5 ml of dialysis buffer (20 mM HEPES [N-2-
hydroxyethylpiperazine-N'-2-ethanesulfonic acid] Na+ [pH
8.0], 0.1 M KCl, 0.2 mM EDTA, 5% glycerol (vol/vol), 1 mM
dithiothreitol) and dialyzed in 1 liter of the same buffer
containing 0.5 mM phenylmethylsulfonyl fluoride. Insoluble
material was removed by centrifugation at 23,000 x gm.(14,000 rpm; SS-34 rotor; Sorvall) for 30 min at 4°C. This was
followed by selective precipitation in the presence of mag-
nesium, a recently described method to purify SR-family
proteins, including SF2/ASF (48, 57, 63). The supernatant
described above was adjusted to 20 mM MgCl2, and the tube
was rocked for 2.5 h at 4°C. The resulting precipitate was
collected and dissolved in 0.5 ml of dialysis buffer. Two
different preparations of partially purified SF2/ASF, approx-
imately 1 mg of protein per ml, were used for the experi-
ments described below. Although SF2/ASF polypeptide is
the predominant protein in these concentrated preparations
(more than 50% pure), other SR proteins known to have
SF2/ASF-like activities (15, 30, 48, 63) are also present.
Further fractionation by Phenyl-Superose (Pharmacia) chro-
matography, as described previously (32), yielded essen-
tially pure SF2/ASF that was devoid of SC35 and other SR
proteins. However, pure HeLa cell SF2/ASF, or recombi-
nant SF2/ASF, could not be obtained in soluble form at as
high a concentration and was therefore only partially active
in the assays reported here. We expect that other SR
proteins are also active in these assays.
The preparation of soluble recombinant hnRNP Al (0.2
mg/ml) in Eschenchia coli was as described previously (44).
Construction of template plasmids. Plasmid pSP64-p6(8/9),
containing a rat ,3-tropomyosin minigene, was derived from
pSP64-p2p6(8/9) (28) by restriction at a unique NcoI site in
the middle of exon 6. The ends were filled in with DNA
polymerase I Klenow fragment and ligated to HindIII link-
ers. The DNA was digested with HindIII and recircularized,
resulting in the removal of exon 5 through the NcoI site of
exon 6 (see Fig. 1). Pre-mRNAs beginning in exon 5 or exon
6 were respectively made by runoff transcription from
pSP64-p2p6(8/9) linearized with BamHI or from pSP64-
p6(8/9) linearized with EcoRI. Template plasmids of the
pSP64-DUP series, containing duplicated human P-globin
first exon, first intron, and second exon units (kindly pro-
vided by R. Kole) (12), were linearized with BamHI. The
DUP23, DUP33, DUP51, and DUP171 constructs have
internal exons of 23, 33, 51, and 175 nucleotides (nt),
respectively (31). Rabbit 0-globin wild-type template plas-
mid, pSP64-Rchr,BG(PvuII-BglII) (kindly provided by M.
Aebi and C. Weissmann) (1), was linearized with AvaI.
In vitro splicing assays. 2P-labeled and 7mGpppG-capped
pre-mRNA substrates were transcribed from each linearized
template DNA with SP6 RNA polymerase essentially as
described previously (34, 46). Standard in vitro splicing
reactions were carried out at 30°C for 3.5 to 4.5 h in 25 ,ul
with the indicated amounts of HeLa cell nuclear extract,
S100 extract, SF2/ASF fraction, and recombinant hnRNP
Al as described previously (36, 47), except that 1 mM
instead of 3.2 mM MgCl2 was used for splicing the ,-tropo-
myosin pre-mRNAs (see Fig. 1). RNA products were ana-
lyzed by electrophoresis on 4% (see Fig. 1), 5.5% (see Fig. 2
and 6), or 6.5% (see Fig. 3 and 5) polyacrylamide-7 M urea
gels followed by autoradiography, as described previously
(46).
RESULTS
SF2/ASF prevents inappropriate exon skipping in a natural
alternatively spliced pre-mRNA. The alternative splicing pat-
tern of rat P-tropomyosin pre-mRNA is regulated in a
tissue-specific manner (27). This pre-mRNA includes two
internal mutually exclusive exons: exon 6, which is used in
fibroblasts and smooth muscle, and exon 7, which is
uniquely used in skeletal muscle (27) (Fig. 1, diagrams).
To study the regulation of j-tropomyosin alternative splic-
ing, we constructed minigenes that include the natural exons
and introns from exon 5 or 6 to exon 8 and include exon 9
prespliced to exon 8. The resulting pre-mRNAs are desig-
nated 5-6-7-8/9 and 6-7-8/9 (the numbers correspond to the
exons; "-" denotes an intron, and "/" denotes splicing). In
agreement with a previous report (28), in vitro splicing in
nuclear extract resulted in skipping of exons 6 and 7 to
generate an inappropriately spliced 5/8/9 RNA (Fig. 1A, lane
1, products indicated by asterisks), which is not observed
from the endogenous ,B-tropomyosin gene in vivo. Upon
addition of SF2/ASF, this inappropriate exon skipping event
was markedly prevented, thereby allowing inclusion of the
fibroblast-type exon 6, the expected pattern for HeLa cells
(Fig. 1A, lanes 2 and 3, products indicated by F). Since
splicing of exon 5 to exon 6 does not occur efficiently in vitro
(28), only a small amount of fully spliced fibroblast-type
5/6/8/9 mRNA was detected, and instead the corresponding
5-6/8/9 intermediate accumulated (Fig. 1A, lanes 2 and 3). An
even greater stimulation of exon 6 to exon 8 splicing, at the
expense of inappropriate exon 5-to-exon 8 skipping, was
obtained with a small amount of SF2/ASF to complement an
S100 extract that is unable to support splicing in the absence
of added SF2/ASF (32) (Fig. 1A, lanes 4 to 6). Compared
with nuclear extract, S100 extract plus SF2/ASF yielded
reduced amounts of pre-mRNA and lariat RNAs (derived
from inappropriate skipping and fibroblast-type splicing)
because of the higher overall splicing efficiency.
The results of the experiment described above show that
SF2/ASF prevents inappropriate exon skipping of the mutu-
ally exclusive tropomyosin exons 6 and 7, a reaction not
observed with the endogenous gene in vivo. In the case of
pre-mRNAs containing alternative 5' splice sites and a
common 3' splice site, hnRNP Al counteracts the effects of
SF2/ASF on proximal 5' splice site selection, thereby caus-
ing activation of distal 5' splice sites (44). Hence, we tested
whether hnRNP Al would also cause inappropriate exon
skipping with the 1-tropomyosin pre-mRNA. Significantly,
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FIG. 1. Effects of SF2/ASF (SF2) on splicing of P-tropomyosin
pre-mRNAs in vitro. The structures of the pre-mRNAs and splicing
products are shown schematically at the top and side of each panel.
The exon and intron sizes are indicated in nucleotides. Alternative
splicing patterns and their products are indicated by S (skeletal
muscle pattern), F (fibroblast pattern), and * (inappropriate splic-
ing). All splicing products were characterized in detail previously
(28) or otherwise identified by their electrophoretic mobilities before
and after enzymatic debranching (58). The sizes of the pBR322/
HpaII DNA markers (lanes M) are shown in nucleotides. (A)
Analysis of splicing products of P-tropomyosin 5-6-7-8/9 pre-
mRNA. The splicing reactions contained nuclear extract (NE) (5 ,ul)
supplemented with SF2/ASF (lane 1, none; lane 2, 2.5 p1; lane 3, 5
,ul) or S100 extract (7 p,l) complemented with SF2/ASF (lane 4, 1 Pl;
lane 5, 2 pl; lane 6, 4 p,l). (B) Analysis of splicing products of
3-trypomyosin 6-7-8/9 pre-mRNA. The reaction mixtures contained
either nuclear extract (5 p,l) plus SF2/ASF (lane 1, none; lane 2, 2.5
p.1; lane 3, 5 p1J) or S100 extract (7 p1) plus SF2/ASF (lane 4, 0.5 p1l;
lane 5, 1 p,l; lane 6, 2 p1).
an excess of hnRNP Al did not promote this kind of
inappropriate exon skipping event (data not shown). Thus,
the in vitro modulation of alternative splicing by hnRNP Al
appears to be restricted to specific types of splice site
competition (see below).
Effect of SF2/ASF on the selection of tissue-specific exons.
Previous in vitro and in vivo studies of rat 1-tropomyosin
pre-mRNA splicing suggested that alternative splicing of
exon 5 to exon 6 (fibroblast pattern) or exon 5 to exon 7
(skeletal muscle pattern) depends on prior joining of either
alternative exon to exon 8 (28). Thus, alternative splicing of
the mutually exclusive exon 6 or 7 to the downstream
common exon 8 appears to be the critical event in this type
of regulated splicing. We therefore tested whether SF2/ASF
can influence this alternative splicing event through its polar
activity on 5' splice site selection.
When transcripts of the 5-6-7-8/9 minigene construct were
used (Fig. 1A, diagram), the predominant modulation caused
by SF2/ASF was a switch from inappropriate exon 5-to-exon
8 skipping (products indicated by asterisks in Fig. 1A) to the
fibroblast splicing pattern (Fig. 1A, lanes 1 to 6, products
indicated by F). However, a small amount of skeletal mus-
cle-type splicing of exon 7 to exon 8 was also specifically
stimulated by SF2/ASF addition (Fig. 1A, lanes 2, 3, and 6,
products indicated by S). Using transcripts of the shorter
6-7-8/9 minigene construct (Fig. 1B, diagram), we observed
strong activation of the proximal skeletal muscle-type splic-
ing (products indicated by S) at the expense of the distal
fibroblast-type splicing (products indicated by F) upon addi-
tion of SF2/ASF (Fig. 1B, lanes 2 to 6).
The quantitative difference in exon 7 inclusion between
the two pre-mRNAs suggests that the factors that block exon
7 use in nonmuscle cells (see Discussion) are more effective
with the longer, more natural substrate. In both cases, the
SF2/ASF-induced changes are consistent with the known
effect of SF2/ASF on alternative 5' splice site selection (16,
33), since the 5' splice site of the fibroblast-type exon 6 is
distal and that of the skeletal muscle-specific exon 7 is
proximal, relative to the downstream common exon 8. Thus,
as previously reported, SF2/ASF activity does not operate in
a sequence-specific manner but rather senses the relative
positions of alternative 5' splice sites (16, 33). Significantly,
the addition of excess hnRNP Al did not counteract the
activation of the exon 7 splice by SF2/ASF (data not shown;
see Discussion).
SF2/ASF promotes alternative exon inclusion. To study the
substrate requirements for splicing modulation by SF2/ASF
and hnRNP Al in detail, a series of model pre-mRNAs
designed to study exon skipping and inclusion (12) were
used. First, we tested the effect of SF2/ASF activity on exon
skipping with these model substrates. In agreement with a
previous report (12), the model pre-mRNAs DUP33 and
DUP23, which include a 33- or 23-nt internal exon, were
spliced predominantly via exon skipping under standard
conditions in HeLa cell nuclear extract (Fig. 2, lane 1; Fig. 3,
lanes 1 and 5). These pre-mRNAs are also spliced via exon
skipping when transiently expressed in HeLa cells (12).
Upon the addition of SF2/ASF to nuclear extract, DUP33
pre-mRNA gave rise to an exon inclusion spliced product,
which was markedly promoted as the concentration of
SF2/ASF increased (Fig. 2, lanes 1 to 4). Accumulation of
531-nt RNAs, in which only one of the two introns has been
excised (12), was also stimulated by SF2/ASF, consistent
with the suppression of exon skipping. Complementation of
S100 extract with SF2/ASF resulted exclusively in exon
inclusion even at low SF2/ASF concentrations (Fig. 2, lanes
4 to 6). The DUP23 substrate also showed stimulation of
exon inclusion in S100 extract complemented with SF2/ASF,
although with reduced efficiency (Fig. 3, lanes 1 and 2). The
partial suppression of exon skipping with this substrate is
also reflected in the accumulation of 521-nt RNAs, in which
one of the two introns was spliced out (Fig. 3, lane 2). Thus,
the ability of SF2/ASF to promote exon inclusion appears to
be dependent on the length of the internal exon.
Abundance of hnRNP Al in HeLa cell nuclear and S100
extracts. The difference in the magnitude of the SF2/ASF
effect in nuclear and S100 extracts suggests that the latter
extract contains less hnRNP Al, which is known to coun-
teract the effect of SF2/ASF on alternative 5' splice site
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FIG. 2. Effects of SF2/ASF (SF2) on splicing of a model P-globin
pre-mRNA in vitro. The structure of the DUP33 model pre-mRNA
(12) is shown schematically. The two introns and their flanking exon
sequences are identical. The exon and intron sizes are indicated in
nucleotides. The structures of unspliced pre-mRNA and of the two
mRNAs resulting from alteinative exon inclusion or skipping are
represented on the right. All splicing products were previously
characterized in detail (12). The sizes of the pBR322/HpaII DNA
markers (lane M) are shown in nucleotides. The reaction mixtures
contained either nuclear extract (NE) (6 Ill) plus SF2/ASF (lanes 1
and 5, none; lane 2, 2 ,ul; lane 3, 4 ILI; lane 4, 8 Ill) or S100 extract
(6 pl) plus SF2/ASF (0.7 p,l) (lane 6).
selection (44). In agreement with this prediction, immuno-
blot analysis with an anti-hnRNP Al monoclonal antibody (a
gift from G. Dreyfuss) demonstrated much lower levels of
hnRNP Al in S100 extract than in nuclear extract (Fig. 4).
Comparison with known amounts of purified recombinant
hnRNP Al indicates that our preparation of nuclear extract
contains approximately 350 ng (10 pmol) of hnRNP Al per p.l
of extract. The concentration ofhnRNP Al in S100 extract is
less than 10-fold lower (30 ng or 0.9 pmol/Vl of extract) (Fig.
4 and data not shown).
In the experiments reported here (e.g., in Fig. 3), the range
of added hnRNP Al was 200 to 800 ng (6 to 23 pmol),
compared with 2.1 pg (61 pmol) in 6 p,l of nuclear extract, or
approximately 10 to 40% of the endogenous hnRNP Al. For
SF2/ASF polypeptide, we calculated a concentration of 150
ng (5.4 pmol)/p,l of nuclear extract and a concentration about
30-fold lower in S100 extract (data not shown). In Fig. 2,
e.g., the endogenous SF2/ASF in 6 ,ul of nuclear extract is
therefore 0.9 pg (32 pmol); we estimate the range of added
SF2/ASF as 0.6 to 2.4 p,g (22 to 87 pmol), or approximately
'60-
V 234 5678 9101112 i3141516
FIG. 3. Effect of alternative exon length on hnRNP Al-promoted
exon skipping. The structures of the 0-globin pre-mRNA (36) and of
the model DUP23-171 derivatives (12) are shown schematically. The
exon and intron sizes are indicated in nucleotides. The upstream (U)
and downstream (D) introns and their adjacent exon sequences are
identical. The alternative spliced products are indicated by triangles
(<1, exon inclusion products; 4, exon skipping products). All
splicing products were previously characterized in detail (12). The
sizes of the pBR322/HpaII DNA markers (lane M) are shown in
nucleotides. The reaction mixtures contained either nuclear extract
alone (NE) (6 ,ul) or S100 extract (6 Iul) plus SF2/ASF (SF2) (0.7 I,l)
plus recombinant hnRNP Al (lanes 2, 6, 10, and 14, none; lanes 3,
7, 11, and 15, 1 ,ul; lanes 4, 8, 12, and 16, 4 p.l).
70 to 270% of the endogenous SF2/ASF. This latter estimate
does not take into account the likely contribution by other
SR polypeptides to the overall SF2/ASF activity. In addi-
tion, the fraction of active SF2 and hnRNP Al molecules in
the extracts and purified preparations is unknown.
hnRNP Al promotes skipping of short internal exons. We
next analyzed the substrate requirements for regulation of
exon skipping by hnRNP Al. It was shown previously, with
the model pre-mRNAs used here, that exon inclusion or
skipping is dependent on the length of the internal alternative
exon in vitro and in vivo (12). In agreement with that study,
the spliced products obtained under standard splicing con-
ditions in HeLa cell nuclear extract gradually switched from
exon skipping to exon inclusion as the length of the internal
exon increased (Fig. 3, lanes 1, 5, 9, atid 13). In S100 extract
complemented with SF2/ASF, the ratio of exon inclusion to
exon skipping significantly increased, relative to the ratio in
nuclear extract, even with the shortest internal exon (Fig. 3,
lanes 1, 2, 5, 6, 9, and 10). The addition of hnRNP Al, under
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FIG. 4. Abundance of hnRNP Al in HeLa cell nuclear and S100
extracts. The indicated amounts of the S100 and nuclear extract
(NE) preparations used throughout this study were analyzed by
immunoblotting. Purified recombinant hnRNP Al (rhnRNP Al) (50
to 200 ng) was used as a concentration standard. Samples separated
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis were
electroblotted onto nitrocellulose, incubated with an anti-hnRNP Al
monoclonal antibody (9H10; a gift from G. Dreyfuss) at a 1/500
dilution, and then subjected to alkaline-phosphatase-based detec-
tion, as described previously (44). The relative mobilities of hnRNP
Al (34 kDa) and its alternatively spliced isoform AlB (38 kDa),
which contains a unique internal exon (7), are indicated. The relative
mobilities of prestained protein size markers (Amersham) are shown
in kilodaltons.
otherwise identical conditions, promoted exon skipping with
the DUP23, DUP33, and DUP51 pre-mRNAs in a concen-
tration-dependent manner (Fig. 3, lanes 2 to 4, 6 to 8, and 10
to 12). This was also reflected at the level of 521-, 531-, and
549-nt RNAs, in which only one of the two introns is spliced
out. An increase in the ratio of exon skipping to exon
inclusion was also seen upon the addition of hnRNP Al to
nuclear extract (data not shown). An excess of hnRNP Al
failed to promote significant exon skipping with the DUP171
pre-mRNA, which contains the longest internal exon (Fig. 3,
lanes 14 to 16). Therefore, there appears to be an upper limit
on the length of the internal alternative exon in order for
hnRNP Al to promote exon skipping, although these partic-
ular substrates do not address the possible contributions of
sequence context and higher-order structure.
A strong upstream polypyrimidine tract prevents hnRNP
Al-induced exon skipping. Another critical parameter that
influences the selection of internal alternative exons in these
model pre-mRNAs is the pyrimidine content of the upstream
3' splice site (12, 13). Thus, the major spliced product of
DUP33 pre-mRNA in nuclear extract is generated by exon
skipping (Fig. 5, lane 1), whereas the mutant transcript
DUP33-Y5, which has an uninterrupted polypyrimidine tract
in the upstream intron, is spliced exclusively by exon
inclusion in vivo (12) and in nuclear extract (lane 5). Splicing
of wild-type DUP33 in S100 extract complemented with
SF2/ASF resulted in partial exon inclusion (Fig. 5, lane 2),
which reverted to exon skipping, as expected, upon hnRNP
Al addition (lanes 3 and 4). In contrast, hnRNP Al addition
failed to promote exon skipping in the case of the mutant
DUP33-Y5 pre-mRNA (Fig. 5, lanes 6 to 8). Splicing of the
DUP33-Yl, -Y2, and -Y3 substrates (12), which have pyri-
midine contents intermediate between those of DUP33 and
DUP33-Y5, showed that hnRNP Al-mediated exon skipping
decreased gradually as the pyrimidine content near the 3'
DUP DUP
33 33-Y5
SFZ SFZ
N Al Al
-..+.IE
-
1>1 -
_ WIN 4- EXON-INCLUSION
*-- EZ EXON-SKIPPING
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FIG. 5. Effect of upstream polypyrimidine tract composition on
hnRNP Al-promoted exon skipping. The structures of the model
pre-mRNAs (12) and the sequences of the polypyrimidine tracts and
3' splice sites in each upstream intron are shown. The dots indicate
the five nucleotide differences (transversions) between the two
templates. The exon and intron sizes are indicated in nucleotides.
The structures of the two mRNAs resulting from alternative exon
inclusion or skipping are represented on the right. All splicing
products were previously characterized in detail (12). The reaction
mixtures contained either nuclear extract alone (NE) (6 p.l) or S100
extract (6 p.l) plus SF2/ASF (SF2) (0.7 ,ul) plus recombinant hnRNP
Al (lanes 2 and 6, none; lanes 3 and 7, 1 ,ul; lanes 4 and 8, 4 pul). Pu,
purine; Py, pyrimidine.
splice site increased (data not shown). These data show that
a strong polypyrimidine tract element, made up of uninter-
rupted pyrimidines, overcomes the modulatory activity of
hnRNP Al that leads to internal exon skipping.
hnRNP Al does not promote inappropriate exon skipping of
a natural constitutively spliced pre-mRNA. The preceding
experiments described above with natural and model alter-
native splicing substrates showed that the stimulation of
exon skipping by hnRNP Al depends on structural features
of the substrates. In the case of the model pre-mRNAs, a
long internal exon or a strong upstream 3' splice site abro-
gated the exon skipping activity of hnRNP Al. We hypoth-
esized that the exon and intron sequences of constitutively
spliced pre-mRNAs have evolved to minimize inappropriate
exon skipping. If this is the case, an excess of hnRNP Al
should not affect the splicing of natural constitutively spliced
pre-mRNAs containing multiple exons.
We chose to analyze the splicing of wild-type rabbit
3-globin pre-mRNA, which contains three exons and two
rhnRNPAI
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FIG. 6. Effect of hnRNP Al on constitutive splicing of rabbit
3-globin pre-mRNA in vitro. The structure of the pre-mRNA is
shown schematically with the exon and intron sizes in nucleotides
(1). The pre-mRNA and final spliced product are represented on the
right. The expected position of the inappropriate exon skipping
product is also indicated on the right. The sizes of the pBR322/Hinfl
DNA markers (lane M) are shown in nucleotides. The characteriza-
tion of the splicing products was described previously (1). The
reaction mixtures contained either nuclear extract alone (NE) (lane
1, 15 pJ) or S100 extract (6 ,ul) plus SF2/ASF (SF2) (0.7 pl) plus
recombinant hnRNP Al (lane 2, none; lane 3, 2 pl; lane 4, 5 pl).
introns (El-E2-E3), because trace amounts of inappropriate
E2 skipping were previously detected with this substrate in
some preparations of nuclear extract (1). Fully spliced
El/E2/E3 mRNA was efficiently generated in nuclear extract
and in S100 extract complemented with SF2/ASF, while an
RNA of the expected size for El/E3, reflecting inappropriate
skipping of E2, could not be detected with our extracts (Fig.
6, lanes 1 and 2). Significantly, the addition of hnRNP Al did
not generate detectable levels of El/E3 mRNA or inhibit
accurate El/E2/E3 splicing (Fig. 6, lanes 2 to 4).
DISCUSSION
Influence of the ratio of SF2/ASF to hnRNP Al on alterna-
tive splicing. Previous work showed that the ratio of SF2/
ASF to hnRNP Al specifies the selection of alternative 5'
splice sites in vitro in the case of pre-mRNAs that contain
alternative 5' splice sites that compete for a common 3'
splice site (44). We have examined whether this system of
two antagonistic protein factors can influence two other
modes of alternative splicing: (i) exon skipping versus exon
inclusion and (ii) the selection of mutually exclusive exons.
In vitro splicing experiments with a series of model
pre-mRNAs designed to study exon skipping and inclusion
demonstrated that, in an appropriate context, the ratio of
SF2/ASF to hnRNP Al can precisely determine whether the
internal exon is included or excluded. An excess of SF2/ASF
promotes exon inclusion, whereas an excess of hnRNP Al
favors exon skipping. These changes in alternative splice site
selection are elicited by small changes in the relative
amounts of hnRNP Al and SF2/ASF, within a range of
concentrations comparable to the endogenous levels of these
factors in HeLa cell nuclear extract. The ability of hnRNP
Al to promote exon skipping depends on the context of the
alternative exon as influenced, for example, by the size of
this exon and by the relative strength of the polypyrimidine
tract in the preceding intron.
A different mode of alternative splicing was studied with
pre-mRNAs derived from a rat ,B-tropomyosin gene. The
natural transcripts from this gene are processed in a tissue-
specific manner, in part by incorporation of the mutually
exclusive exons 6 and 7 (Fig. 1A, diagram). Previous muta-
tional analyses identified critical cis-acting elements, within
exon 7 and in the adjacent upstream intron, that specifically
block the use of the skeletal muscle-specific exon 7 in
nonmuscle cells in vivo (23, 29). It was shown that the lack
of exon 7 utilization in nonmuscle cells is due not to a simple
cis competition mechanism but rather to the action of
trans-acting factors that block the use of this exon in certain
cellular environments (23). A protein factor that binds spe-
cifically to the regulatory region upstream of exon 7 was
recently purified from HeLa cells by using a gel mobility
shift assay (23, 51) and shown to be identical to PTB, a
previously identified polypyrimidine tract-binding protein
(19, 52), one isoform of which is also known as hnRNP I (4,
18, 53). This was an unexpected finding, since the regulatory
element is not composed of consecutive pyrimidines (23, 51).
Whereas the binding of PTB may be involved in the negative
regulation of exon 7 inclusion, no trans-acting factors that
positively promote inclusion of this exon in skeletal muscle
have been documented. In the present study, we showed
that SF2/ASF influences alternative splicing of ,3-tropomyo-
sin in vitro, allowing inclusion of exon 7 in a nonmuscle cell
extract. In this particular instance, hnRNP Al did not
antagonize SF2/ASF to inhibit use of the proximal exon 7
and promote use of the distal exon 6.
The mechanism by which SF2/ASF promotes the P-tropo-
myosin skeletal muscle-specific splicing pattern in HeLa cell
extracts remains unknown. One possibility is that activation
of the proximal 5' splice site downstream of exon 7 by excess
SF2/ASF overcomes the negative regulation exerted by PTB
and/or other factors at the regulatory elements located
upstream of, and within, exon 7. Alternatively, the exon 7
blocking factor(s) could be a specific target for SF2/ASF, or
the two factors may compete for binding to the same
sequence, e.g., the regulatory element in the intron preced-
ing exon 7. In this regard, we note that hnRNP Al, a known
antagonist of SF2/ASF (44), was also reported to bind at 3'
splice sites under splicing conditions in nuclear extract (60).
Perhaps the blocking factor(s) stoichiometrically antago-
nizes SF2/ASF during splicing of P-tropomyosin pre-mRNA,
in a manner analogous to that of hnRNP Al with many other
pre-mRNAs. The concentration of SF2/ASF protein (rela-
tive to the concentration of hnRNP Al) varies considerably
in different cell lines and tissues (25). Hence, it is possible
that regulation of the ratio of SF2/ASF to PTB and/or to
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other factors plays an important role in the tissue-specific
control of,B-tropomyosin alternative splicing.
Although SF2/ASF is able to promote inclusion of exon 7
in vitro, it is unclear how this relates to the regulated
inclusion of this exon in muscle cells in vivo. Transient
transfection experiments with wild-type and mutant rat
3-tropomyosin minigenes revealed that blockage of the
skeletal muscle-specific exon 7 in nonmuscle cells is prima-
rily the result of inhibition of the 3' splice site of exon 7 (22).
However, any changes in activities that alter the relative use
of the 5' splice site of exon 7, and hence the relative balance
of splice site competition, could lead to alterations in normal
splicing regulation. The observed effects of SF2/ASF on
P-tropomyosin in vitro splicing may reflect the additional
influence of this factor on alternative 3' splice site selection
(15). This activity ofSF2/ASF is not counteracted by hnRNP
Al but rather by an activity designated SF7 (45). Further
purification and characterization of SF7 will be necessary
before we can assess whether the ratio of SF2/ASF to SF7
can also influence exon skipping or exon inclusion with the
substrates described here.
We note that highly purified SF2/ASF polypeptide showed
somewhat reduced activity in some of the assays described
here compared with concentrated preparations that contain
additional SR polypeptides with SF2/ASF activity, as origi-
nally defined (15, 16, 30, 32, 33, 48, 63). Therefore, it is
possible that individual SR polypeptides make different
qualitative or quantitative contributions to the exon inclu-
sion properties reported here.
Influence of the ratio of SF2/ASF to hnRNP Al on consti-
tutive splicing. Our data obtained with natural and model
pre-mRNAs support the idea that the activity of the general
splicing factor SF2/ASF on splice site selection might be part
of the normal cellular mechanisms that prevent exon skip-
ping and ensure the fidelity of constitutive splicing (33). We
found that appropriate amounts of SF2/ASF effectively
prevented inappropriate exon skipping in rat 3-tropomyosin
pre-mRNA. In addition, we found that the ability of hnRNP
Al to promote exon skipping by counteracting SF2/ASF is
substrate dependent. Some of the important structural pa-
rameters of the substrate appear to be the length of the
alternative exon and the relative strength of the preceding 3'
splice site. We interpret these results as indicating that the
ratio of SF2/ASF to hnRNP Al affects splice site selection
when there is an appropriate balance of cis competition
strengths between the relevant splice sites. The same struc-
tural parameters should influence presumptive interactions
between factors bound at the splice sites of adjacent introns,
which result in exon definition (20, 38, 56, 61). Hence,
SF2/ASF and hnRNP Al could be involved in some of the
molecular interactions responsible for exon definition. In
addition, the ability of hnRNP Al to influence splice site
selection may be restricted by the presence of specific
sequences that render the substrate susceptible to regulation
by other factors, as in the case of j-tropomyosin.
hnRNP Al did not cause inappropriate exon skipping in
vitro either with a constitutively spliced rabbit P-globin
pre-mRNA or with an alternatively spliced rat P-tropomyo-
sin pre-mRNA. Since hnRNP Al is an abundant nuclear
protein (2, 53), the fact that it is unable to promote exon
skipping indiscriminately in vitro is significant. Thus, even
high levels of hnRNP Al, as are found in proliferating cells
(8, 11, 39, 49, 54), should not result in inappropriate exon
skipping of constitutively spliced pre-mRNAs in vivo, al-
though they may be responsible for the altered patterns of
alternative splicing of numerous cellular pre-mRNAs ob-
served in transformed cells, as previously suggested (3, 44).
Although multiple copies of hnRNP Al are probably bound
to most, if not all, cellular pre-mRNAs in a ribonucleosome
structure (9), the phasing of these ribonucleosomes on
individual pre-mRNAs may influence splice site selection.
High-affinity binding of hnRNP Al to specific sequences that
may be present on only certain pre-mRNAs could position
the ribonucleosomes, resulting in the observed substrate
specificity in hnRNP Al-mediated exon skipping. The kinet-
ics of binding by hnRNP Al and other hnRNP proteins (4,
44, 51) to different pre-mRNAs, relative to other splicing
factors, may also determine the precise outcome of splice
site selection for each substrate.
We propose that constitutive splice sites have evolved in
conjunction with appropriate sequence and structural con-
texts to match exclusively appropriate pairs of 5' and 3'
splice sites so as to avoid exon skipping, regardless of
variations in the levels of SF2/ASF, hnRNP Al, SF7, and
similar regulatory factors. In contrast, alternative splice sites
that are in cis competition have more balanced relative
strengths and are therefore susceptible to variations in the
levels of such factors.
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